Early Diagnosis

hATTR risk can be identified through genomic screening and guide management early on, preventing potential diagnostic and treatment delays. Read Article ›

Wild-type transthyretin amyloidosis remains a clinical challenge, exacerbated by diagnostic delays. Read Article ›

Researchers evaluated patient characteristics that may be associated with positive technetium pyrophosphate uptake and aid in the diagnosis of cardiac transthyretin amyloidosis. Read Article ›

Considerable cardiovascular disease burden is often seen in patients with hereditary transthyretin amyloidosis in the 5 years preceding diagnosis. Read Article ›

A complete diagnostic workup is critical to ensure accurate subtyping, with the recognition that both transthyretin and light chain amyloidosis can occur concurrently. Read Article ›

Researchers are developing an algorithm to interpret and manage abnormal monoclonal protein studies in the context of presumed ATTR. Read Article ›

Investigations of subclinical features in hATTR are warranted to understand the potential role of early disease-modifying treatment. Read Article ›

Diagnosis of this disease is often missed and still underdiagnosed, despite recent diagnostic improvements and the use of scintigraphy. Read Article ›

The inclusion of patients who also have cardiac amyloidosis in clinical trials evaluating treatments for heart failure with preserved ejection fraction may help explain the underperformance of drugs that are effective in other forms of heart failure. Read Article ›

Clinical signals and features of positive PYP transthyretin cardiac amyloidosis highlight the need for early diagnosis. Read Article ›

Page 1 of 2

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to recieve: